Two types of primary mucinous ovarian tumors can be distinguished based on their origin

• Published in: Modern pathology Vol. 33; no. 4; pp. 722 - 733
• Main Authors: Simons, Michiel, Simmer, Femke, Bulten, Johan, Ligtenberg, Marjolijn J., Hollema, Harry, van Vliet, Shannon, de Voer, Richarda M., Kamping, Eveline J., van Essen, Dirk F., Ylstra, Bauke, Schwartz, Lauren E., Wang, Yihong, Massuger, Leon F., Nagtegaal, Iris D., Kurman, Robert J.
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.04.2020; Elsevier Limited
• Subjects: 13/51; 14/63; 38/23; 38/32; 631/1647/514/2254; 631/1647/664/1257; 631/208/68; 631/67/1517/1709; 692/53/2421; 82/1; Adenocarcinoma, Mucinous - chemistry; Adenocarcinoma, Mucinous - genetics; Adenocarcinoma, Mucinous - pathology; Adult; Antigens; Baltimore; Biomarkers, Tumor - analysis; Biomarkers, Tumor - genetics; Brenner Tumor - chemistry; Brenner Tumor - genetics; Brenner Tumor - pathology; Copy number; Cystadenoma, Mucinous - chemistry; Cystadenoma, Mucinous - genetics; Cystadenoma, Mucinous - pathology; Databases, Factual; Disease Progression; ErbB-2 protein; Female; Fluorescence in situ hybridization; Gene Dosage; Genetic Predisposition to Disease; Genomes; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Laboratory Medicine; Matrix Attachment Region Binding Proteins - analysis; Medicine; Medicine & Public Health; Middle Aged; Mutation; Myc protein; Netherlands; Ovarian cancer; Ovarian Neoplasms - chemistry; Ovarian Neoplasms - genetics; Ovarian Neoplasms - pathology; Ovaries; p53 Protein; Pathology; Phenotype; Proto-Oncogene Proteins c-myc - genetics; Proto-Oncogene Proteins p21(ras) - genetics; Receptor, ErbB-2 - genetics; Teratoma; Teratoma - chemistry; Teratoma - genetics; Teratoma - pathology; Transcription Factors - analysis; Tumor Suppressor Protein p53 - genetics; Tumors; Netherlands; Baltimore
• ISSN: 0893-3952; 1530-0285
• DOI: 10.1038/s41379-019-0401-y

The origin of primary mucinous ovarian tumors is unknown. We explore the hypothesis that they originate from either Brenner tumors or teratomas and examine differences between the tumors that arise in these settings. A total of 104 Brenner tumor-associated mucinous tumors and 58 teratoma-associated mucinous tumors were analyzed. Immunohistochemistry for 21 antigens and fluorescence in situ hybridization for ERBB2 and MYC were performed. Genome-wide copy number analysis and mutation analysis for 56 cancer-related genes was carried out on a subset of mucinous ovarian tumors and their complementary Brenner tumor or teratoma. Patients with teratoma-associated mucinous tumors were significantly younger than patients with Brenner tumor-associated mucinous tumors (43 vs. 61 years). During progression from cystadenoma to atypical proliferative mucinous (borderline) tumor to carcinoma expression of typical gastrointestinal markers was increased in both Brenner tumor-associated and teratoma-associated mucinous tumors. Brenner tumor-associated mucinous tumors showed more frequently calcifications and Walthard cell nests, rarely expressed SATB2 and showed more often co-deletion of CDKN2A and MTAP . Teratoma-associated mucinous tumors were characterized by mucinous stromal dissection, SATB2 expression and RNF43 mutations. Other frequent mutations in both Brenner tumor-associated and teratoma-associated mucinous tumors were TP53 and KRAS mutations. Based on identical mutations or copy number profiles clonal relationships were indicated in two mucinous tumors and their associated Brenner tumor. Teratomas and Brenner tumors give rise to different subtypes of mucinous ovarian tumors. Subsequent progression pathways are comparable since both Brenner tumor-associated and teratoma-associated mucinous tumors develop a gastrointestinal immunophenotype during progression and show early mutations in KRAS and TP53 . Teratoma-associated mucinous tumors may more closely resemble true gastrointestinal tumors, indicated by their expression of SATB2 and the presence of RNF43 mutations.